The Latest Analyst Ratings For Alignment Healthcare
Portfolio Pulse from Benzinga Insights
Alignment Healthcare (NASDAQ:ALHC) has received mixed analyst ratings over the last three months, with a shift towards a more bearish stance in the last 30 days. The average 12-month price target for ALHC has increased to $9.25 from $8.88. Analysts from firms like Barclays, UBS, Stifel, Raymond James, and Stephens & Co. have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Alignment Healthcare, a provider of Medicare Advantage plans, has shown impressive revenue growth of 28.63% as of December 31, 2023, but struggles with profitability and efficient asset utilization, as indicated by its net margin, ROE, and ROA.

March 06, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alignment Healthcare has seen a recent shift towards more bearish analyst ratings, with an updated average 12-month price target of $9.25. Despite impressive revenue growth, the company faces challenges in profitability and asset utilization.
The mixed analyst ratings and the recent bearish shift suggest uncertainty about ALHC's future stock performance. However, the increase in the average price target indicates some optimism. The company's strong revenue growth is a positive sign, but issues with profitability and asset utilization could dampen investor enthusiasm in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100